AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Core Viewpoint - AEON Biopharma has received acceptance from NYSE American for its plan to regain compliance with listing standards, allowing until August 3, 2026, to meet requirements related to market capitalization and stockholders' equity [1][2]. Group 1: Compliance and Listing Standards - NYSE American has granted AEON a Plan Period until August 3, 2026, to regain compliance with continued listing standards [2]. - The company will undergo periodic reviews by NYSE American during the Plan Period to assess progress [2]. - Failure to regain compliance or make sufficient progress may lead to delisting proceedings by NYSE American [2]. Group 2: Company Overview - AEON Biopharma is focused on developing its proprietary botulinum toxin complex, ABP-450, for various therapeutic indications, initially targeting the neurosciences market [3]. - ABP-450 is the same botulinum toxin complex marketed for cosmetic use as Jeuveau by Evolus and is manufactured in compliance with cGMP [3]. - The product has received biosimilar approval in Mexico and India, with exclusive development and distribution rights in the U.S., Canada, EU, UK, and other territories [3]. Group 3: Management and Expertise - The company has assembled a highly experienced management team with specific expertise in biopharmaceutical and botulinum toxin development and commercialization [3].